Business Context and Reporting Period
Company: electroCore, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: July 13, 2020
Reporting Period: Single event date (July 13, 2020)
electroCore, Inc. is a Delaware corporation listed on the NASDAQ Global Select Stock Market under the symbol ECOR. The company is designated as an emerging growth company.
Key Financial Metrics
This filing is a Current Report (Form 8-K) regarding a specific corporate event and does not contain financial statements, revenue figures, profit data, cash flow, margins, debt levels, or liquidity metrics. The filing text does not provide a clear value for any financial performance indicators.
Material Changes
The material event reported is the issuance of an Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA) for the company's gammaCore Sapphire device.
- Authorization Scope: Use of gammaCore Sapphire non-invasive vagus nerve stimulation (nVNS) at home or in a healthcare setting.
- Indication: Acute treatment of adult patients with known or suspected COVID-19 experiencing exacerbation of asthma-related dyspnea and reduced airflow.
- Condition: Applies to patients for whom approved drug therapies are not tolerated or provide insufficient symptom relief.
Outlook, Risks, and Management Commentary
Management Commentary: The company issued a press release (Exhibit 99.1) to announce the FDA EUA.
Risks and Uncertainties: The filing explicitly states that there can be no assurance as to what impact, if any, the EUA for gammaCore Sapphire will have on the Company, its business, operations, or financial condition.
Guidance: No financial guidance or forward-looking projections regarding revenue or earnings were provided in this document.
Investor Verification Checklist
- Verify the full text of the press release filed as Exhibit 99.1 for specific details on the EUA scope and limitations.
- Review the FDA's official announcement regarding the Emergency Use Authorization for gammaCore Sapphire to confirm regulatory status.
- Monitor subsequent filings (10-Q or 10-K) to assess the actual financial impact of this authorization on revenue and operations.
- Check for any updates on the commercialization strategy for the device in the context of the COVID-19 pandemic.